Abortion Pill Access in Flux: Providers Adapt After Fifth Circuit and Supreme Court Rulings

On Friday, May 1, Megan Jeyifo, executive director of the Chicago Abortion Fund, was preparing for a fundraising event when she received breaking news about a court decision that severely limited nationwide access to the abortion pill mifepristone. She immediately sent a staff-wide message on Slack:

"Mifepristone by telehealth is no longer accessible for anyone seeking abortion care in the country. We’re working to understand what this will mean for our grantees who are receiving telehealth now and in the short term. We know how critical telehealth abortion care is, and this is a very difficult thing to digest."

Across the reproductive health landscape, similar messages were sent to staff as providers everywhere grappled with the sudden unanimous decision from the Fifth Circuit Court of Appeals. Their ruling granted Louisiana’s request for an injunction against FDA rule changes from 2023, which had allowed blue-state telehealth providers to send mifepristone to thousands of patients monthly in states where abortion is banned. More than a quarter of abortions in the U.S. occur via telemedicine.

By Monday, the U.S. Supreme Court temporarily reinstated access to mifepristone, which, when combined with misoprostol, is prescribed to induce an abortion or aid in a miscarriage. The Supreme Court is now expected to issue a final decision in the case as early as Thursday.

Providers Prepare for Potential Restrictions

Abortion providers, directors of major abortion funds, and support hotlines told reporters this week that they are ready to address patients’ needs even if further restrictions on mifepristone are imposed. Many anticipate offering patients misoprostol-only protocols for their abortions. A misoprostol-only protocol can be just as effective, though it may cause more side effects.

"Telehealth providers aren’t going away," said April Lockley, medical director of the Miscarriage + Abortion Hotline. "Through all the confusion and potential legal changes, we’re all here to stay and support abortion seekers."

Abortions with mifepristone will still be available for in-person treatment at clinics. Since the May 1 ruling, many providers have noted increased orders for this medication.

"Getting pills in advance of the need for them is a strategy that we have proposed and advocated for for years now," said Elisa Wells, co-founder of Plan C, an online campaign focused on abortion pill access. Their website traffic has also increased since the Louisiana ruling.

"Any challenge to abortion access in the United States by the anti-choice movement is designed to instill fear, confusion, and chaos. These court cases are no different."

Providers and abortion funds expressed concern about misleading headlines implying that all medication abortion was now banned.

"I think letting people know abortion is still legal is just really important," Jeyifo said.

What’s Next for Mifepristone Access?

As the Supreme Court prepares to rule on the case, providers are bracing for potential changes. Clinics are stockpiling mifepristone, and funds are exploring alternative protocols to ensure patients can still access care. The outcome of the Supreme Court’s decision will determine the future of medication abortion access in the U.S.